What is the Return on Assets (ROA) of Oncology Pharma this year?
The Return on Assets (ROA) of Oncology Pharma is 0 undefined this year.
Oncology Pharma ROA 2024
Oncology Pharma ROA
0
Ticker
ONPH
ISIN
US68235J2015
WKN
A2QEWD
In 2024, Oncology Pharma's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year.
Oncology Pharma Aktienanalyse
What does Oncology Pharma do?
Oncology Pharma Inc is a global biotechnology company working on the development of therapies and medications against various types of cancer. The company was founded in the USA in 2011 and is headquartered in Boston, Massachusetts. Its business model is based on developing and marketing medications focused on fighting cancer. The company specializes in targeted therapies, immunotherapies, and combination therapies. Oncology Pharma's products have the potential to revolutionize cancer treatment and improve the lives of millions of people worldwide. Oncology Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Oncology Pharma's Return on Assets (ROA)
Oncology Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Oncology Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Oncology Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Oncology Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Oncology Pharma stock
What was the ROA of Oncology Pharma compared to the previous year?
The ROA of Oncology Pharma has increased by 0% compared to the previous year.
What consequences do high ROA have for investors of Oncology Pharma?
A high ROA is advantageous for investors of Oncology Pharma, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Oncology Pharma?
A low ROA can be unfavorable for investors of Oncology Pharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Oncology Pharma affect the company?
An increase in ROA of Oncology Pharma can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Oncology Pharma impact the company?
A reduction in the ROA of Oncology Pharma can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Oncology Pharma?
Some factors that can influence the ROA of Oncology Pharma include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Oncology Pharma important for investors?
The ROA of Oncology Pharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Oncology Pharma take to improve ROA?
To improve ROA, Oncology Pharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Oncology Pharma pay?
Over the past 12 months, Oncology Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncology Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of Oncology Pharma?
The current dividend yield of Oncology Pharma is .
When does Oncology Pharma pay dividends?
Oncology Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oncology Pharma?
Oncology Pharma paid dividends every year for the past 0 years.
What is the dividend of Oncology Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oncology Pharma located?
Oncology Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oncology Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oncology Pharma from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.
When did Oncology Pharma pay the last dividend?
The last dividend was paid out on 9/26/2024.
What was the dividend of Oncology Pharma in the year 2023?
In the year 2023, Oncology Pharma distributed 0 USD as dividends.
In which currency does Oncology Pharma pay out the dividend?
The dividends of Oncology Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Oncology Pharma
Our stock analysis for Oncology Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncology Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Oncology Pharma Revenue
- Oncology Pharma Net Income
- Oncology Pharma P/E
- Oncology Pharma P/S
- Oncology Pharma EBIT
- Oncology Pharma Dividend
- Oncology Pharma Stocks
- Oncology Pharma Market capitalization
- Oncology Pharma Debt
- Oncology Pharma Liabilities
- Oncology Pharma Equity
- Oncology Pharma AAQS
- Oncology Pharma Employees
- Oncology Pharma ROE
- Oncology Pharma ROA
- Oncology Pharma ROCE
